Neladalkib (NVL-655) + Alectinib
Phase 3RecruitingInterest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Trial Timeline
Jul 17, 2025 → Dec 1, 2029
NCT ID
NCT06765109About Neladalkib (NVL-655) + Alectinib
Neladalkib (NVL-655) + Alectinib is a phase 3 stage product being developed by Nuvalent for Non-small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06765109. Target conditions include Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06765109 | Phase 3 | Recruiting |
Competing Products
20 competing products in Non-small Cell Lung Cancer